Imaging the dopamine transporter: Varrone and Halldin provide an overview of the most commonly used SPECT and PET radioligands for dopamine transporter imaging and review current applications in neurologic and psychiatric disorders. Page 1331
Imaging β-cell mass: Bormans comments on challenges in noninvasive quantification of β-cell mass and previews an article in this issue of JNM on 11C-dihydrotetrabenazine, a PET tracer with promise for longitudinal assessment in therapies for diabetes. Page 1335
PET and prognosis in chemotherapy: Cerci and colleagues assess the prognostic value of 18F-FDG PET after 2 cycles of chemotherapy in patients with early and advanced Hodgkin lymphoma, including those classified as at high and low risk. Page 1337
Erlotinib response monitoring with PET: Aukema and colleagues evaluate the role of integrated 18F-FDG PET/CT in early identification of response to an epidermal growth factor receptor tyrosine kinase inhibitor in non–small cell lung cancer. Page 1344
Response prediction in NETs: Haug and colleagues investigate the utility of 68Ga-DOTATATE PET/CT for early prediction of progression and clinical outcomes after a first cycle of peptide receptor radionuclide treatment in patients with well-differentiated neuroendocrine tumors. Page 1349
Aortic inflammation in COPD: Coulson and colleagues use 18F-FDG PET to assess vascular inflammation in patients with chronic obstructive pulmonary disease to elucidate the mechanisms of increased risk of cardiovascular disease in this cohort. Page 1357
Posttherapy SPECT/CT in thyroid cancer: Grewal and colleagues explore whether 131I SPECT/CT changes the need for additional cross-sectional imaging after 131I therapy in patients with different types of thyroid carcinoma or modifies conventional thyroid risk-of-recurrence classifications. Page 1361
PET volume reproducibility: Hatt and colleagues establish the repeatability and reproducibility limits of several volume-related 18F-FDG and 18F-FLT PET image–derived indices commonly used in clinical practice. Page 1368
Efficacy and toxicity after 90Y spheres: Strigari and colleagues implement radiobiologic models for tumor control and normal-tissue complication probabilities to describe more effectively local response and liver toxicity rates in 90Y-sphere selective internal radiation therapy in nonresectable hepatocellular carcinoma. Page 1377
18F-FAZA modeling: Shi and colleagues report on a feasibility study to assess hypoxia kinetic models using voxelwise cross-analysis between uptake of the perfusion tracer 15O-H2O and the hypoxia tracer 18F-fluoroazomycin arabinoside. Page 1386
New human reporter gene: Likar and colleagues describe a series of human-derived, pyrimidine-specific reporter genes based on human deoxycytidine kinase and suitable for clinical PET during treatment with acycloguanosine-based cytotoxic drugs. Page 1395
Neuroinflammation in subcortical stroke: Thiel and colleagues use diffusion tensor image–guided 11C-PK11195 PET to identify activated microglia in vivo after stroke in a longitudinal study investigating temporal dynamics and relating microglial activity to pyramidal tract damage. Page 1404
CB1 PET in Huntington disease: Van Laere and colleagues measure type 1 cannabinoid receptor, a crucial modulator of synaptic transmission, in the brains of patients with Huntington disease and healthy controls. Page 1413
Probes for dementia: Kadir and Nordberg provide an educational overview of imaging techniques in neurodegenerative disorders causing dementia, including Alzheimer disease, frontotemporal dementia, dementia with Lewy bodies, and dementia in Parkinson disease. Page 1418
MR-based attenuation correction: Catana and colleagues address attenuation correction challenges in combined PET/MRI and introduce a method based on MRI data from a single dedicated sequence, with utility in a PET/MRI human brain scanner prototype. Page 1431
11C-DTBZ binding in pancreas: Fagerholm and colleagues assess the islet and vesicular monoamine transporter 2 specificity of 11C-dihydrotetrabenazine and describe its potential in PET imaging of pancreatic β-cell mass in type 1 diabetes. Page 1439
18F-FLT PET in ENT1-knockout mice: Paproski and colleagues determine whether equilibrative nucleoside transporter 1 is important for 18F-FLT uptake in normal tissues and tumors. Page 1447
Multimodality imaging of SSTR2: Chen and colleagues report on the development of a somatostatin receptor–enhanced green fluorescent protein fusion construct for nuclear and fluorescent multimodality imaging. Page 1456
PET-based nucleoside tracer transport: Plotnik and colleagues examine the relative roles of different nucleoside PET transport mechanisms on uptake and retention of thymidine, fluorothymidine, and FMAU. Page 1464
76Br-MBBG PET for tumor imaging: Watanabe and colleagues label meta-bromobenzylguanidine with 76Br, a positron emitter, and evaluate its potential as a PET tracer in norepinephrine transporter–expressing tumors. Page 1472
Biodistribution/dosimetry of 18F-AV-133: Lin and colleagues investigate the biodistribution and radiation dosimetry of a potential vesicular monoamine transporter 2 imaging agent, with encouraging results in humans. Page 1480
ON THE COVER
Preliminary results suggest that a new MRI-based attenuation correction method may be as accurate as the segmented CT method and applicable to quantitative neurologic PET/MRI studies. Selection of the linear attenuation coefficient for bone affects PET data quantification, as shown in these representative images of relative changes for 3 attenuation correction models.
See page 1434.
- © 2010 by Society of Nuclear Medicine